1 January 2020 in Journal of Korean Academy of Nursing Administration
김혜숙, et al. J Korean Acad Nurs Adm. 2020 Jun;26(3):218-229. https://doi.org/10.11111/jkana.2020.26.3.218
16 November 2004 in Blood
Non-myeloablative (NST) transplantation is increasingly used in the treatment of patients with AML and MDS who are not candidates for myeloblative transplant. Relapse of disease remains a major cause of treatment failure after NST. Predictive factors to identify patients at high risk of relapse are needed to identify patients who would benefit from additional interventions. Attainment of a high degree of donor engraftment achieved early after transplantation may indicate the presence of a more significant allo-immune effect. We have performed a retrospective analysis of 64 patients with AML and MDS receiving NST, assessing the impact of donor chimerism when measured early after transplantation on outcome. Overall survival (OS), progression free survival (PFS) and risk of graft versus host disease (GVHD) were compared for patients achieving ≥90 % or <90% donor derived hematopoiesis when measured 1 month after transplant. All patients received fludarabine 30 mg/m2/day x 4 days and intravenous busulfan (Busulfex)0.8 mg/kg/day x 4 days for conditioning. All patients received calcineurin-inhibitor based GVHD prophylaxis. All patients received PBSC with G-CSF at 5 mcg/kg beginning day 1 after transplantation. Chimerism was measured using FISH for sex mismatched patient donor pairs or by STR analysis. 37 patients had ≥90% donor derived hematopoiesis, 27 patients had <90% donor derived hematopoiesis after transplantation. The two groups had similar characteristics with a median age of 57 yrs (range 21–70) for patients ≥90% and 58 yrs (range 32–69) for patients <90%. Of patients achieving ≥90%, 23 patients had AML and 14 MDS. Of patients <90%, 13 had AML and 14 with MDS. 7 of 16 (44%) patients with early stage disease(AML in CR1 or early stage MDS) achieved ≥90% donor hematopoiesis, while 30 of 48 (63%) patients with advanced disease achieved ≥90%. 17 of 29 (59%) patients with unrelated donors achieved ≥90% donor derived hematopoiesis, while 20 of 33 (61%) patients with matched related donors achieved ≥90% donor derived hematopoiesis. 21 of 32 (66%) patients with donor-recipeint sex mismatch achieved ≥90% while 16 of 32 (50%) patients with same sex donors were ≥90%. The median follow-up for surviving patients achieving ≥90% donor chimerism was 12 months and 15 months for those <90%. Patients achieving ≥90% donor chimerism had a significantly improved 1-year (71% versus 41%) and 2-year (39% versus 19%) OS (p=0.05). Similarly, for patients achieving ≥90% donor chimerism, there was a trend toward an improved PFS at 1-year (49% versus 30%) and 2-years (32% versus 19%) (p=0.08). There was no difference in the risk of developing stage 2–4 acute GVHD, 19% for both patients above and below 90%. Achieving high levels of donor chimerism when measured early after NST predicts for an improved overall survival and there is a trend toward an improved progression free survival. This may represent the presence of an enhanced graft versus leukemia effect in these patients. The degree of donor chimerism does not predict the development of acute GVHD. These results suggest that patients with <90% donor derived hematopoiesis may be candidates for strategies to enhance donor chimerism.
19 November 2010 in Blood
Abstract 1257 CD4+CD25+Foxp3+ regulatory T cells (Treg) are known to play an important role in the maintenance of peripheral tolerance and control of cGVHD. Recent studies have shown that Treg undergo extensive homeostatic proliferation after allogeneic HSCT. However, highly proliferating Treg are also susceptible to apoptosis and the inability to maintain adequate Treg survival may contribute to the development of cGVHD. Thus, mechanisms of Treg survival and persistence are of great importance. Telomeres are repetitive DNA sequences, located at the ends of each chromosome. Telomeres gradually shorten with each cell division and eventually lead to cell senescence and death. In rapidly dividing cells, telomere length is maintained by telomerase, a reverse transcriptase that prevents premature senescence. Previous studies have shown that abnormal telomerase activity is found in T cells from patients with autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, suggesting that telomerase may play a role in the maintenance of immune tolerance. In the present study, we examined whether telomerase activity and telomere length were associated with Treg homeostasis after allogeneic HSCT, particularly in the context of cGVHD. We examined Treg and conventional CD4 T cells (Tcon) in 35 patients with hematologic malignancies (median age 54 yr) who survived without relapse for more than 2 years after HSCT. Patient samples were obtained at 43 months (median, range: 25–99 months) after HSCT. The severity of cGVHD was classified according to NIH criteria. At the time of analysis, 2 patients had no cGVHD, 19 had mild cGVHD, 9 had moderate cGVHD, and 5 had severe cGVHD. CD4+CD25-CD127+ Tcon and CD4+CD25+CD127- Treg were isolated by flow cytometric cell sorting. Relative telomere length was measured by real time PCR. Telomerase activity was measured by PCR-ELISA. Telomere length was significantly shorter in Treg compared to Tcon in all patients (0.05 vs 0.28; p<0.01), but there was no correlation between telomere length and severity of cGVHD (see Table below) in both Treg and Tcon. Telomerase activity was increased in Treg compared to Tcon (29.73 vs 8.95; p<0.01). In contrast to telomere length, telomerase activity of Treg is significantly associated with severity of cGVHD (38.89 in patients with no or mild cGVHD vs. 8.19 in patients with moderate or severe GVHD, p=0.0002). These data indicate that induction of telomerase activity in Treg after allogeneic HSCT does not prevent overall telomere shortening. However, activation of telomerase appears to increase the replicative life span of Treg and provides a mechanism for maintaining survival of these cells in vivo. In contrast, failure to activate telomerase in some patients may lead to shortened survival of Treg, inability to maintain peripheral tolerance and development of severe cGVHD. : comparison for no/mild vs moderate/severe No relevant conflicts of interest to declare.
30 August 2021 in Korean Association Of Victimology